KBC Group NV Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

KBC Group NV lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 296.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 136,647 shares of the biopharmaceutical company’s stock after purchasing an additional 102,198 shares during the quarter. KBC Group NV’s holdings in Regeneron Pharmaceuticals were worth $97,338,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Mizuho Securities USA LLC grew its stake in shares of Regeneron Pharmaceuticals by 625.5% in the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock worth $62,382,000 after buying an additional 51,162 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock valued at $181,961,000 after acquiring an additional 2,828 shares during the last quarter. Simplify Asset Management Inc. grew its position in Regeneron Pharmaceuticals by 50.8% in the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock worth $10,082,000 after acquiring an additional 3,231 shares in the last quarter. Catalytic Wealth RIA LLC bought a new stake in Regeneron Pharmaceuticals during the third quarter worth approximately $1,334,000. Finally, Daiwa Securities Group Inc. raised its position in Regeneron Pharmaceuticals by 12.3% during the third quarter. Daiwa Securities Group Inc. now owns 20,384 shares of the biopharmaceutical company’s stock valued at $21,428,000 after purchasing an additional 2,234 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 2.7 %

Shares of Regeneron Pharmaceuticals stock opened at $675.79 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The stock has a market cap of $74.26 billion, a price-to-earnings ratio of 16.72, a PEG ratio of 1.59 and a beta of 0.10. The firm’s 50-day moving average is $727.19 and its two-hundred day moving average is $936.96. Regeneron Pharmaceuticals, Inc. has a 1 year low of $666.25 and a 1 year high of $1,211.20.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Citigroup cut their target price on Regeneron Pharmaceuticals from $895.00 to $795.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 14th. Oppenheimer cut their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. BMO Capital Markets cut their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Finally, Canaccord Genuity Group started coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective on the stock. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $1,015.38.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.